Featured Research

from universities, journals, and other organizations

Cholesterol-lowering statin drugs can reduce the risk of stroke, but sometimes should be avoided, study suggests

Date:
August 20, 2011
Source:
Loyola University Health System
Summary:
For many patients, cholesterol-lowering statin drugs can reduce the risk of strokes as well as heart attacks. However, neurologists caution that statins may not be appropriate for certain categories of patients who are at-risk for stroke.

For many patients, cholesterol-lowering statin drugs can reduce the risk of strokes as well as heart attacks. But in a review article, Loyola University Health System neurologists caution that statins may not be appropriate for cetain categories of patients who are at risk for stroke.

The article, by Dr. Murray Flaster and colleagues, appears in the August issue of the journal Expert Review of Neurotherapeutics.

A landmark 2006 study known as SPARCL, published in the New England Journal of Medicine, found that in patients who have experienced strokes or transient ischemic attacks (mini strokes), statins reduced the risk of subsequent strokes by 16 percent.

But this benefit generally applies only to patients who have experienced ischemic strokes, which are caused by blood clots in brain vessels. About 85 percent of strokes are ischemic.

And even among ischemic stroke patients, there is a small subgroup that should be placed on statin therapy only "with circumspection," the researchers write. These patients are those who have had strokes in small blood vessels, have poorly controlled high blood pressure and consume more than one drink of alcohol per day.

The picture is more varied for the 15 percent of stroke patients who have had hemorrhagic strokes (caused by bleeding on or in the brain). There are two types of hemorrhagic stroke: aneurysmal subarachnoid hemorrhage (SAH) and intracranial hemorrhage (ICH). An SAH stroke involves bleeding over the surface of the brain, while an ICH stroke involves bleeding inside the brain.

Statins have been postulated to help recovery in patients with SAH. While the jury is still out, "the overall evidence slightly favors a benefit," researchers wrote.

But high-dose statin therapy "should be avoided as routine therapy in ICH patients until the competing risks and benefits are better understood," the researchers wrote.

Complicating matters further, if a patient whom is on statins experiences an SAH or ICH stroke, he or she should remain on the drugs in the short run. "Reassessment of continuing statin utility in these patients should be considered immediately after recovery," researchers write.

Flaster and his colleagues wrote that more research is needed: "Clearly, the potential influences of statins are so broad and mixed and the potential for effects and countereffects so likely that both careful science and detailed clinical investigation, especially well-designed clinical trials, will be needed to realize and document effective and safe therapeutic intervention."

Flaster is an associate professor in the departments of Neurology and Neurological Surgery at Loyola University Chicago Stritch School of Medicine. He also is medical director of Loyola's outpatient neurology clinic.

Co-authors are Drs. Sarkis Morales-Vidal, Michael J. Schneck and José Biller. Morales-Vidal is an assistant professor in the Department of Neurology. Schneck is a professor in the departments of Neurology and Neurological Surgery and medical director of the Neurosciences ICU. Biller is a professor in the departments of Neurology and Neurological Surgery and chairman of the department of Neurology.


Story Source:

The above story is based on materials provided by Loyola University Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. Murray Flaster, Sarkis Morales-Vidal, Michael J Schneck, José Biller. Statins in hemorrhagic stroke. Expert Review of Neurotherapeutics, 2011; 11 (8): 1141 DOI: 10.1586/ern.11.101

Cite This Page:

Loyola University Health System. "Cholesterol-lowering statin drugs can reduce the risk of stroke, but sometimes should be avoided, study suggests." ScienceDaily. ScienceDaily, 20 August 2011. <www.sciencedaily.com/releases/2011/08/110819092427.htm>.
Loyola University Health System. (2011, August 20). Cholesterol-lowering statin drugs can reduce the risk of stroke, but sometimes should be avoided, study suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/08/110819092427.htm
Loyola University Health System. "Cholesterol-lowering statin drugs can reduce the risk of stroke, but sometimes should be avoided, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/08/110819092427.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins